Skip to main content
. 2022 Feb 3;21:100389. doi: 10.1016/j.lanwpc.2022.100389

Figure 1.

Figure 1

Estimated vaccine efficacies of BNT162b2, AZD1222 and CoronaVac vaccines from PRNT50 titre distributions. The mean PRNT50 titres of vaccinees against the hypothetical variants of concern were assumed to decrease by 2, 4, 7, and 10 folds respectively compared with the PRNT50 titres against the original virus strain. The vaccine efficacies were estimated by bootstrapping the PRNT50 titres of 100 vaccinees by 1000 times. The error bars showed the 95% CI of the estimates with the uncertainty from PRNT50 titre distributions. (A) Vaccine efficacy in reducing susceptibility to infection (σm). (B) Vaccine efficacy in reducing infectiousness if infected (σt). (C) Vaccine efficacy in reducing symptomatic disease and hospital admission (σs).